Disease progression velocity as predictor of severity in Guillain-Barre syndrome.

Rev Peru Med Exp Salud Publica

Servicio de Enfermedades Infecciosas y Tropicales, Hospital Daniel A. Carrión, Huancayo, Perú.

Published: July 2021

Objective: To identify the velocity of disease progression as a predictor of severity in patients with Guillain-Barre syndrome (GBS).

Materials And Methods: Prospective observational study of patients with confirmed diagnosis of GBS between May and August 2019 in four hospitals in Peru. The disease progression velocity (DPV) was defined as the time since the onset of neurological symptoms and the maximum peak of neurological severity.

Results: Of 94 cases with GBS, the average age was 42 years; 73 (77.8%) patients presented severe GBS, the average hospital stay was 19 days; 45 (47.8%) patients haddiarrheal symptoms previously, in 63 (67.1%) patients the onset of motor weakness was located in the upper limbs and in 31 (32.9%) it was located in the lower limbs, 9 (10.0%) patients presented some type of dysautonomy; admission to mechanical ventilation was needed in 8 (8.5%) patients, and the deceased were 2 (2.0%). The DPV≤ 1 day has a 79% probability of developing severe disease, the two and three day DPV have the probability of 61% and 38% respectively of progressing to severe forms.

Conclusion: DPV is a predictor of poor prognosis when it is less than 2 days and with a possible requirement for mechanical ventilation. The speed of progression of neurological disease is a practical and accessible clinical evaluation method that should be evaluated in patients with GBS.

Download full-text PDF

Source
http://dx.doi.org/10.17843/rpmesp.2021.381.5106DOI Listing

Publication Analysis

Top Keywords

disease progression
12
progression velocity
8
predictor severity
8
guillain-barre syndrome
8
patients
8
gbs average
8
patients presented
8
mechanical ventilation
8
disease
5
velocity predictor
4

Similar Publications

Gastric cancer is an aggressive malignancy characterized by significant clinical heterogeneity arising from complex genetic and environmental interactions. This study employed single-cell RNA sequencing, using the 10 × Genomics platform, to analyze 262,532 cells from gastric cancer samples, identifying 32 distinct clusters and 10 major cell types, including immune cells (e.g.

View Article and Find Full Text PDF

Parkinson Disease (PD) is a complex neurological disorder attributed by loss of neurons generating dopamine in the SN per compacta. Electroencephalogram (EEG) plays an important role in diagnosing PD as it offers a non-invasive continuous assessment of the disease progression and reflects these complex patterns. This study focuses on the non-linear analysis of resting state EEG signals in PD, with a gender-specific, brain region-specific, and EEG band-specific approach, utilizing recurrence plots (RPs) and machine learning (ML) algorithms for classification.

View Article and Find Full Text PDF

Non-small cell lung cancer (NSCLC) has emerged as one of the most prevalent malignancies worldwide. N6-methyladenosine (mA) methylation, a pervasive epigenetic modification in long noncoding RNAs (lncRNAs), plays a crucial role in NSCLC progression. Here, we report that mA modification and the expression of the lncRNA stem cell inhibitory RNA transcript (SCIRT) was significantly upregulated in NSCLC tissues and cells.

View Article and Find Full Text PDF

Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent Cohort.

Int J Gynecol Pathol

January 2025

Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-related neoplasm, in which traditional histologic grading does not show prognostic significance. Tumor budding was associated with poorer outcomes in OCCC in previous studies. We aimed to evaluate the prognostic significance of tumor budding in OCCC in an independent cohort.

View Article and Find Full Text PDF

Extracellular vesicles (EVs) are generated in all cells. Systemic administration of allogenic EVs derived from epithelial and mesenchymal cells has been shown to be safe, despite carrying an array of functional molecules, including thousands of proteins. To address whether epithelial cell-derived EVs can be modified to acquire the capacity to induce an immune response, we engineered 293T EVs to harbor the immunomodulatory molecules CD80, OX40L, and PD-L1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!